Search for a trial

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE

This study has been transitioned to CTIS with ID 2024-513992-42-00 check the CTIS register for the current data. The primary objective of this study is to assess whether abelacimab is non-inferior to dalteparin for preventing VTE recurrence through…

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and
bleeding in patients with cancer associated VTE (ASTER)

This study has been transitioned to CTIS with ID 2023-509569-19-00 check the CTIS register for the current data. The primary objective of this study is to assess whether abelacimab is non-inferior to apixaban for preventing VTE recurrence at 6…